Finch is rapidly deploying its human-first discovery platform to a broad range of diseases linked to dysbiosis of the gut microbiome. We are systematically exploring the most promising diseases by generating and analyzing interventional data to empirically determine whether microbial interventions have a meaningful clinical impact. We are deploying our machine learning platform against these datasets to evaluate whether a synthetic ecology is likely to be efficacious, or whether a whole-community microbiota therapy utilizing our Aquashell™ delivery technology is more promising. Finch currently has four active discovery programs aimed at addressing important unmet medical needs.